Indication
Escherichia coli pneumonia
*Escherichia coli* pneumonia is an acute lower respiratory tract infection characterized by bacterial inflammation and consolidation of the pulmonary parenchyma caused by the Gram-negative bacillus *Escherichia coli*. Read more about Escherichia coli pneumonia
253 drugs 100 manufacturers
Drugs that treat it
Common Escherichia coli pneumonia therapies.
GENTAMICIN SULFATE (gentamicin sulfate/PF)
AMIKACIN SULFATE
CIPROFLOXACIN
AZTREONAM
TEFLARO (ceftaroline fosamil acetate)
TEFLARO (ceftaroline fosamil acetate)
AMIKACIN SULFATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soon*Escherichia coli* pneumonia is an acute lower respiratory tract infection characterized by bacterial inflammation and consolidation of the pulmonary parenchyma caused by the Gram-negative bacillus *Escherichia coli*.
While it can present as a community-acquired infection, it most commonly develops as a hospital-acquired or ventilator-associated pneumonia in older adults, hospitalized patients, or immunocompromised individuals with underlying comorbidities such as diabetes mellitus, chronic lung disease, or recent abdominal or urinary tract pathologies.
Pathophysiologically, the organism infects the lungs via microaspiration of colonized oropharyngeal secretions or through hematogenous seeding secondary to a concurrent bacteremia.
Clinically, affected patients present with fever, cough, purulent sputum, dyspnea, and pulmonary infiltrates on chest imaging, often carrying a high risk of bacteremia, pleural empyema, respiratory failure, and sepsis.
- nih.gov
*Escherichia coli* pneumonia is an acute lower respiratory tract infection characterized by bacterial inflammation and consolidation of the pulmonary parenchyma caused by the Gram-negative bacillus *Escherichia coli*
- ovid.com
*Escherichia coli* pneumonia is an acute lower respiratory tract infection characterized by bacterial inflammation and consolidation of the pulmonary parenchyma caused by the Gram-negative bacillus *Escherichia coli* Pathophysiologically, the organism infects the lungs via microaspiration of colonized oropharyngeal secretions or through hematogenous seeding secondary to a concurrent bacteremia Clinically, affected patients present with fever, cough, purulent sputum, dyspnea, and pulmonary infilt...
- nih.gov
While it can present as a community-acquired infection, it most commonly develops as a hospital-acquired or ventilator-associated pneumonia in older adults, hospitalized patients, or immunocompromised individuals with underlying comorbidities such as diabetes mellitus, chronic lung disease, or recent abdominal or urinary tract pathologies Clinically, affected patients present with fever, cough, purulent sputum, dyspnea, and pulmonary infiltrates on chest imaging, often carrying a high risk of ba...
- nih.gov
While it can present as a community-acquired infection, it most commonly develops as a hospital-acquired or ventilator-associated pneumonia in older adults, hospitalized patients, or immunocompromised individuals with underlying comorbidities such as diabetes mellitus, chronic lung disease, or recent abdominal or urinary tract pathologies
- nih.gov
While it can present as a community-acquired infection, it most commonly develops as a hospital-acquired or ventilator-associated pneumonia in older adults, hospitalized patients, or immunocompromised individuals with underlying comorbidities such as diabetes mellitus, chronic lung disease, or recent abdominal or urinary tract pathologies
- nih.gov
Pathophysiologically, the organism infects the lungs via microaspiration of colonized oropharyngeal secretions or through hematogenous seeding secondary to a concurrent bacteremia Clinically, affected patients present with fever, cough, purulent sputum, dyspnea, and pulmonary infiltrates on chest imaging, often carrying a high risk of bacteremia, pleural empyema, respiratory failure, and sepsis
- conference-correspondent.com
Pathophysiologically, the organism infects the lungs via microaspiration of colonized oropharyngeal secretions or through hematogenous seeding secondary to a concurrent bacteremia Clinically, affected patients present with fever, cough, purulent sputum, dyspnea, and pulmonary infiltrates on chest imaging, often carrying a high risk of bacteremia, pleural empyema, respiratory failure, and sepsis
Personalize your experience
Follow Escherichia coli pneumonia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.